Enovis Corporation (NYSE: ENOV) has entered a binding offer to acquire eCential Robotics, a Grenoble-based developer of an open robotic surgery platform, in a deal announced on September 1, 2026. Enovis will pay an upfront enterprise value of €155 million - about €176 million in cash to shareholders at closing - plus up to €35 million in milestone-based contingent consideration. The transaction is expected to close by year-end 2026 pending French works council consultation and regulatory approvals.
A robotic complement to ARVIS and ASTRA
eCential Robotics has spent more than 15 years building a modular platform that unifies 2D/3D robotic imaging, real-time navigation and robotics for spine and orthopaedic bone surgery. Unlike closed systems, eCential's platform hosts third-party apps from implant partners including Spineart, ChoiceSpine, Nexxt Spine and Amplitude Surgical. Enovis plans to layer that on top of its ARVIS augmented reality surgical guidance system and the ASTRA enabling technology platform.
A robotics centre of excellence in Grenoble
The deal will establish a robotics centre of excellence in Grenoble, a French medical-technology hub that also hosts stakeholders including CEA-Leti and multiple orthopaedic labs. eCential CEO Clement Vidal and founder Stephane Lavallee - who founded the company in 2009 after previous careers building French computer-assisted surgery pioneers - will both remain involved. "Enovis brings focus, speed, and a real commitment to the future of eCential Robotics," Lavallee said in the announcement.
Financial impact and funding
Enovis will fund the transaction with balance-sheet cash and its existing revolver. Management guided that the deal will create roughly 150 basis points of dilution to 2027 adjusted EBITDA margin, offset by 50 basis points of underlying improvement for a net 100 bps headwind. Free cash flow conversion is expected to climb above 50% in 2027 as the ARVIS-eCential portfolio scales.
Surgical robotics keeps consolidating
The acquisition lands in a surgical-robotics market that is actively consolidating around AI-enabled platforms. It follows recent moves by CMR Surgical to win FDA clearance for Versius Plus, a broader wave of medtech and AI M&A, and rising investor interest in platform companies that combine imaging, navigation and robotic arms.
Reporting based on the Enovis press release, GlobeNewswire and eCential Robotics disclosures.